Bisphosphonate treatment in primary breast cancer: Results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancerBent Bruun Kristensen, Jonas Bergh, Bent Ejlertsen et al.|Acta Oncologica|2008Cited by 71
A randomised feasibility/phase II study (SBG 2004-1) with dose-dense/tailored epirubicin, cyclophoshamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancerSara Margolin, Mats Hellström, Per Karlsson et al.|Acta Oncologica|2010Cited by 19
Tailored Dose-Dense Versus Standard Adjuvant Chemotherapy for High-Risk Early Breast Cancer: End-of-Study Results of the Randomized PANTHER TrialAlexios Matikas, I. Thalmann, Volker Möbus et al.|Journal of Clinical Oncology|2024Cited by 11
Dose-tailoring of FEC adjuvant chemotherapy based on leukopenia is feasible and well tolerated. Toxicity and dose intensity in the Scandinavian Breast Group phase 3 adjuvant Trial SBG 2000-1Per Edlund, Carl Blomqvist, Johan Ahlgren et al.|Acta Oncologica|2011Cited by 11
Long-term safety and survival outcomes from the Scandinavian Breast Group 2004-1 randomized phase II trial of tailored dose-dense adjuvant chemotherapy for early breast cancerAlexios Matikas, Jonas Bergh, Sara Margolin et al.|Breast Cancer Research and Treatment|2017Cited by 8